Physician profile
J Ruegemer
NPI 1326007709
$95,320.65
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $27K · 2021: $1,850.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $90,414.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $3,767.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $743.38 | 2020 | |
| Medtronic Minimed, INC. | $62.79 | 2019-2020 | |
| Insulet Corporation | $62.69 | 2019-2020 | |
| Amgen INC. | $54.22 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $50.60 | 2019-2020 | |
| Dexcom, INC. | $36.71 | 2020 | |
| Companion Medical, INC. | $34.73 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $32.17 | 2019 | |
| Valeritas, INC. | $13.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.39 | 2019 | |
| Tandem Diabetes Care, INC. | $12.23 | 2019 | |
| Radius Health, INC. | $11.79 | 2020 | |
| Novo Nordisk INC | $11.16 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Ruegemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.